| Cellular senescence promotes adverse effects of chemotherapy and cancer relapse M Demaria, MN O'Leary, J Chang, L Shao, SU Liu, F Alimirah, K Koenig, ... Cancer discovery 7 (2), 165-176, 2017 | 1112 | 2017 |
| Late‐life rapamycin treatment reverses age‐related heart dysfunction JM Flynn, MN O'Leary, CA Zambataro, EC Academia, MP Presley, ... Aging cell 12 (5), 851-862, 2013 | 314 | 2013 |
| Rapamycin‐mediated mTORC 2 inhibition is determined by the relative expression of FK 506‐binding proteins KH Schreiber, D Ortiz, EC Academia, AC Anies, CY Liao, BK Kennedy Aging cell 14 (2), 265-273, 2015 | 176 | 2015 |
| The ribosomal protein Rpl22 controls ribosome composition by directly repressing expression of its own paralog, Rpl22l1 MN O'Leary, KH Schreiber, Y Zhang, ACE Duc, S Rao, JS Hale, ... PLoS genetics 9 (8), e1003708, 2013 | 125 | 2013 |
| Muscle-specific 4E-BP1 signaling activation improves metabolic parameters during aging and obesity S Tsai, JM Sitzmann, SG Dastidar, AA Rodriguez, SL Vu, CE McDonald, ... The Journal of clinical investigation 125 (8), 2952-2964, 2015 | 119 | 2015 |
| Increased 4E-BP1 expression protects against diet-induced obesity and insulin resistance in male mice SY Tsai, AA Rodriguez, SG Dastidar, E Del Greco, KL Carr, JM Sitzmann, ... Cell reports 16 (7), 1903-1914, 2016 | 66 | 2016 |
| Rapamycin reverses metabolic deficits in lamin A/C-deficient mice CY Liao, SS Anderson, NH Chicoine, JR Mayfield, EC Academia, ... Cell reports 17 (10), 2542-2552, 2016 | 56 | 2016 |
| Chronic rapamycin treatment or lack of S6K1 does not reduce ribosome activity in vivo MG Garelick, VL MacKay, A Yanagida, EC Academia, KH Schreiber, ... Cell Cycle 12 (15), 2493-2504, 2013 | 37 | 2013 |
| Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov 7: 165–176 M Demaria, MN O’Leary, J Chang, L Shao, S Liu, F Alimirah, K Koenig, ... Article CAS, 2017 | 27 | 2017 |
| Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017; 7: 165–76 M Demaria, MN O’Leary, J Chang, L Shao, S Liu, F Alimirah, K Koenig, ... | 23 | |
| Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017; 7 (2): 165–176. doi: 10.1158/2159-8290 M Demaria, MN O'Leary, J Chang, L Shao, S Liu, F Alimirah, K Koenig, ... CD-16-0241.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 22 | |
| Evidence that S6K1, but not 4E-BP1, mediates skeletal muscle pathology associated with loss of A-type lamins CY Liao, SS Anderson, NH Chicoine, JR Mayfield, BJ Garrett, CS Kwok, ... Cell Discovery 3 (1), 1-15, 2017 | 16 | 2017 |
| Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies EC Academia, CM Mejías-De Jesús, JS Stevens, LY Jia, T Yankama, ... Journal of Managed Care & Specialty Pharmacy 27 (10), 1438-1446, 2021 | 14 | 2021 |
| EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates D Sentana-Lledo, E Academia, H Viray, D Rangachari, SS Kobayashi, ... Translational Lung Cancer Research 12 (7), 1590, 2023 | 9 | 2023 |
| Longitudinal functional study of murine aging: a resource for future study designs DS Evans, MN O'Leary, R Murphy, M Schmidt, K Koenig, M Presley, ... Journal of Bone and Mineral Research Plus 5 (3), e10466, 2021 | 9 | 2021 |
| Opioid prescribing after discharge in a previously mechanically ventilated, opioid-naïve cohort EC Academia, CJ Gabriel, A Mueller, KA Schwarz, K Bartels, RJ Valuck, ... Annals of Pharmacotherapy 54 (11), 1065-1072, 2020 | 8 | 2020 |
| Evaluation of First-Dose, Intravenous Push Penicillins and Carbapenems in the Emergency Department EC Academia, JE Jenrette, SW Mueller, JM McLaughlin J Pharm Prac, 2020 | 5 | 2020 |
| Tumor lysis syndrome (TLS) in acute myeloid leukemia (AML) patients treated with azacitidine (AZA) and venetoclax (VEN). JQ Huang, E Academia, DA Pollyea, JA Gutman, A Hammes, S Chase, ... Journal of Clinical Oncology 38 (15_suppl), e19507-e19507, 2020 | 3 | 2020 |
| A real-world study of patient characteristics and clinical outcomes in EGFR-mutated lung cancer treated with first-line osimertinib. H Viray, A Piper-Vallillo, P Widick, E Academia, M Shea, D Rangachari, ... Journal of Clinical Oncology 40 (16_suppl), e21033-e21033, 2022 | 1 | 2022 |
| A review of PI3K Inhibitors in b-cell malignancies L Cannon, EC Academia, AE Glode Journal of the Advanced Practitioner in Oncology 10 (7), 715, 2019 | 1 | 2019 |
